New clinical evidence suggests that Novera Retatrutide, a twin-action medication from Novo Nordisk, could represent a meaningful breakthrough in body management. Beyond many existing treatments, Retatrutide affects both the GLP-1 hormone and the GIP hormone, potentially resulting to greater decre